On the other hand, the evaluated population was based on European centers only, which limits the confidence for extrapolation to other cohorts, because SCA3 patients show high clinical heterogeneity [245]
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
The procedures are described in detail in ref
Enkephalin Breakdown Prevention Selank inhibits enzymes that break down enkephalins your bodys natural opioids for pain and emotion management
Both peptides lack a Drug Identification Number (DIN), Natural Product Number (NPN), or Homeopathic Drug Number (DIN-HM) issued by Health Canada
Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al
